{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:40:38Z","timestamp":1790916038196,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005883","name":"Hertz Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005883","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This perspective brings together multiple observations concerning the regulatory architecture and functional interactions of the\n                    <jats:italic>TP53<\/jats:italic>\n                    gene and its isoforms. The\n                    <jats:italic>TP53<\/jats:italic>\n                    gene encompasses an internal enhancer-promoter region (P2) located between exons 2 and 5, which is transactivated by full-length\u00a0TAp53\u03b1, to drive the expression of truncated\n                    <jats:italic>TP53<\/jats:italic>\n                    isoforms \u0394N133p53\u03b1, \u03b2 or \u03b3. \u0394N133p53\u03b1 homo-monomers or dimers very likely form hetero-tetramers with homo-dimers of full-length TAp53\u03b1. The\u00a0TAp53\u03b1-\u0394N133p53 tetramer then acts as a transcription factor augmenting mitochondrial efficiency, DNA repair, telomere restoration and reversing cellular senescence, thus opposing many outputs of tumor suppressive TAp53\u03b1 homo-tetramers. Other transcription factors, such as estrogen receptor (ER),\u00a0OCT1, and SOX9 also may bind the P2 promoter-enhancer to promote transcription of oncogenic\n                    <jats:italic>TP53\u00a0<\/jats:italic>\n                    isoforms. These transcription factors, together with full-length TAp53\u03b1, appear to cooperate to maintain an open chromatin state in the P2 region in a manner reminiscent of a neural \u201cassociative memory\u201d network.\n                  <\/jats:p>","DOI":"10.1038\/s41418-026-01822-6","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:11:41Z","timestamp":1785517901000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Associative memory plays a role in ER-1\u03b1 positive breast cancers"],"prefix":"10.1038","author":[{"given":"Dan","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hoyos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6153-8793","authenticated-orcid":false,"given":"Benjamin","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5821-9548","authenticated-orcid":false,"given":"Yael","family":"Aylon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4311-7172","authenticated-orcid":false,"given":"Moshe","family":"Oren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1871-6387","authenticated-orcid":false,"given":"Arnold J.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"1822_CR1","doi-asserted-by":"publisher","unstructured":"Levine AJ, Hainaut P. The TP53 gene Contains a Diversity Box that makes it more than a Tumor Suppressor Gene, 2026, Cell Death Diff Cell Death Differ. 2026. https:\/\/doi.org\/10.1038\/s41418-026-01681-1","DOI":"10.1038\/s41418-026-01681-1"},{"key":"1822_CR2","doi-asserted-by":"publisher","unstructured":"Surget S, Khoury MP, and Bourdon J-C. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets Therapy 2013;7 57\u201368. https:\/\/doi.org\/10.2147\/OTT.S53876.","DOI":"10.2147\/OTT.S53876"},{"key":"1822_CR3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","volume":"20","author":"AJ Levine","year":"2020","unstructured":"Levine AJ. p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020;20:471\u201380. https:\/\/doi.org\/10.1038\/s41568-020-0262-1.","journal-title":"Nat Rev Cancer"},{"key":"1822_CR4","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1101\/gad.1987810","volume":"24","author":"E Ungewitter","year":"2010","unstructured":"Ungewitter E, Scrable H. \u039440p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs. Genes Dev. 2010;24:2408\u201319. https:\/\/doi.org\/10.1101\/gad.1987810.","journal-title":"Genes Dev"},{"key":"1822_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/acel.12192","volume":"13","author":"M Pehar","year":"2014","unstructured":"Pehar M, Ko MH, Li M, Scrable H, Puglielli L. P44, the \u2018longevity-assurance\u2019 isoform of P53, regulates tau phosphorylation and is activated in an age-dependent fashion. Aging Cell. 2014;13:449\u201356. https:\/\/doi.org\/10.1111\/acel.12192.","journal-title":"Aging Cell"},{"key":"1822_CR6","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1474-9726.2010.00547.x","volume":"9","author":"M Pehar","year":"2010","unstructured":"Pehar M, O\u2019Riordan KJ, Burns-Cusato M, Andrzejewski ME, del Alcazar CG, Burger C, et al. Altered longevity-assurance activity of p53:p44 in the mouse causes memory loss, neurodegeneration and premature death. Aging Cell. 2010;9:174\u201390. https:\/\/doi.org\/10.1111\/j.1474-9726.2010.00547.x.","journal-title":"Aging Cell"},{"key":"1822_CR7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/cdd.2011.152","volume":"19","author":"V Marcel","year":"2012","unstructured":"Marcel V, Petit I, Murray-Zmijewski F, Goullet de Rugy T, Fernandes K, Meuray V, et al. Diverse p63 and p73 isoforms regulate \u0394133p53 expression through modulation of the internal TP53 549 promoter activity. Cell Death Differ. 2012;19:816\u201326.","journal-title":"Cell Death Differ"},{"key":"1822_CR8","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1038\/onc.2010.266","volume":"29","author":"V Marcel","year":"2010","unstructured":"Marcel V, Vijayakumar V, Fern\u00e1ndez-Cuesta L, Hafsi H, Sagne C, Hautefeuille A, et al. p53 regulates the transcription of its \u0394133p53 isoform through specific response elements contained within the TP53 P2 internal promoter. Oncogene. 2010;29:2691\u20132700. https:\/\/doi.org\/10.1038\/onc.2010.266.","journal-title":"Oncogene"},{"key":"1822_CR9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2317735121","volume":"121","author":"C Roselle","year":"2024","unstructured":"Roselle C, Horikawa I, Chen L, Kelly AR, Gonzales D, Da T, et al. Enhancing chimeric antigen receptor T cell therapy by modulating the p53 signaling network with \u0394133p53\u03b1. Proc Natl Acad Sci USA. 2024;121:e2317735121. https:\/\/doi.org\/10.1073\/pnas.2317735121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1822_CR10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2402533121","volume":"121","author":"AJ Levine","year":"2024","unstructured":"Levine AJ. Improving T cell killing and understanding senescence: Possible roles for TP53 in cancer immunotherapy. PNAS USA. 2024;121:e2402533121. https:\/\/doi.org\/10.1073\/pnas.2402533121.","journal-title":"PNAS USA"},{"key":"1822_CR11","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1093\/jmcb\/mjz060","volume":"11","author":"Y Liu","year":"2019","unstructured":"Liu Y, Tavana O, Gu W. P53 modifications : Exquisite decorations of the powerful guardian. J Mol Cell Biol. 2019;11:554\u201377.","journal-title":"J Mol Cell Biol"},{"key":"1822_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp2229","volume":"10","author":"D Lu","year":"2024","unstructured":"Lu D, Faizi M, Drown B, Simerzin A, Fran\u00e7ois J, Bradshaw G, et al. Temporal regulation of gene expression through integration of p53 dynamics and modifications. Sci Adv. 2024;10:eadp2229. https:\/\/doi.org\/10.1126\/sciadv.adp2229.","journal-title":"Sci Adv"},{"key":"1822_CR13","doi-asserted-by":"publisher","DOI":"10.15252\/msb.202110588","volume":"18","author":"A Jim\u00e9nez","year":"2022","unstructured":"Jim\u00e9nez A, Lu D, Kalocsay M, Berberich MJ, Balbi P, Jambhekar A, et al. Time-series transcriptomics and proteomics reveal alternative modes to decode p53 oscillations. Mol Syst Biol. 2022;18:e10588. https:\/\/doi.org\/10.15252\/msb.202110588.","journal-title":"Mol Syst Biol"},{"key":"1822_CR14","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/s41418-022-00980-7","volume":"29","author":"D Hoyos","year":"2022","unstructured":"Hoyos D, Greenbaum B, Levine AJ. The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein. Cell Death Differ. 2022;29:938\u201345. https:\/\/doi.org\/10.1038\/s41418-022-00980-7.","journal-title":"Cell Death Differ"},{"key":"1822_CR15","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.3390\/cancers12092472","volume":"12","author":"RA Eiholzer","year":"2020","unstructured":"Eiholzer RA, Mehta S, Kazantseva M, Drummond CJ, McKinney C, Young K, et al. Intronic TP53 Polymorphisms Are Associated with Increased \u0394133TP53 Transcript, Immune Infiltration and Cancer Risk. Cancers. 2020;12:2472. https:\/\/doi.org\/10.3390\/cancers12092472.","journal-title":"Cancers"},{"key":"1822_CR16","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.14734","volume":"5","author":"G Gadea","year":"2016","unstructured":"Gadea G, Arsic N, Fernandes K, Diot A, Joruiz SM, Abdallah S, et al. TP53 drives invasion through expression of its \u0394133p53\u03b2 variant. Elife Sep. 2016;5:e14734. https:\/\/doi.org\/10.7554\/eLife.14734.","journal-title":"Elife Sep"},{"key":"1822_CR17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/jmg.2005.037952","volume":"43","author":"G Bougeard","year":"2006","unstructured":"Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet. 2006;43:531\u20133. https:\/\/doi.org\/10.1136\/jmg.2005.037952.","journal-title":"J Med Genet"},{"key":"1822_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100982","volume":"42","author":"Galante","year":"2025","unstructured":"Galante, Guardia PAF, Pisani GDA, Sandoval J, Barros-Filho RL, Gifoni MC, et al. Personalized screening strategies for TP53 R337H carriers: a retrospective cohort study of tumor spectrum in Li-Fraumeni syndrome adult carriers. Lancet Regional Health Am. 2025;42:100982. https:\/\/doi.org\/10.1016\/j.lana.2024.100982.","journal-title":"Lancet Regional Health Am"},{"key":"1822_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41418-023-01236-8","volume":"31","author":"AJ Levine","year":"2024","unstructured":"Levine AJ, Carpten JD, Murphy M, et al. Exploring the genetic and molecular basis of differences in multiple myeloma of individuals of African and European descent. Cell Death Differ. 2024;31:1\u20138. https:\/\/doi.org\/10.1038\/s41418-023-01236-8.","journal-title":"Cell Death Differ"},{"key":"1822_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/mc.2940040103","volume":"4","author":"G Lozano","year":"1991","unstructured":"Lozano G, Levine AJ. Tissue-specific expression of p53 in transgenic mice is regulated by intron sequences. Mol Carcinogenes. 1991;4:3\u20139. https:\/\/doi.org\/10.1002\/mc.2940040103.","journal-title":"Mol Carcinogenes"},{"key":"1822_CR21","doi-asserted-by":"publisher","first-page":"4747","DOI":"10.1093\/nar\/19.17.4747","volume":"19","author":"SW Beenken","year":"1991","unstructured":"Beenken SW, Karsenty G, Raycroft L, Lozano G. An intron binding protein is required for transformation ability of p53. Nucleic Acids Res. 1991;19:4747\u201352. https:\/\/doi.org\/10.1093\/nar\/19.17.4747.","journal-title":"Nucleic Acids Res"},{"key":"1822_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1158\/1541-7786.MCR-21-0583","volume":"20","author":"EM Pinto","year":"2022","unstructured":"Pinto EM, Maxwell KN, Halalsheh H, Phillips A, Powers J, MacFarland S, et al. Clinical and Functional Significance of TP53 Exon 4-Intron 4 Splice Junction Variants. Mol Cancer Res MCR. 2022;20:207\u201316. https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0583.","journal-title":"Mol Cancer Res MCR"},{"key":"1822_CR23","doi-asserted-by":"publisher","first-page":"11217","DOI":"10.1074\/jbc.M107391200","volume":"277","author":"K Kato","year":"2002","unstructured":"Kato K, Horiuchi S, Takahashi A, Ueoka Y, Arima T, Matsuda T, et al. Contribution of estrogen receptor alpha to oncogenic K-Ras-mediated NIH3T3 cell transformation and itsimplication for escape from senescence by modulating the p53 pathway. J Biol Chem. 2002;277:11217\u201324. https:\/\/doi.org\/10.1074\/jbc.M107391200.","journal-title":"J Biol Chem"},{"key":"1822_CR24","doi-asserted-by":"publisher","first-page":"30117","DOI":"10.1074\/jbc.M112.367326","volume":"287","author":"CE Berger","year":"2012","unstructured":"Berger CE, Qian Y, Liu G, Chen H, Chen X. p53, a target of estrogen receptor (ER) \u03b1, modulates DNA damage-induced growth suppression in ER-positive breast cancer cells. J Biol Chem. 2012;287:30117\u201327. https:\/\/doi.org\/10.1074\/jbc.M112.367326.","journal-title":"J Biol Chem"},{"key":"1822_CR25","doi-asserted-by":"crossref","unstructured":"Aylon Y, Furth N, Pirona A, Lavie A, Federova O, Hassin O, et al. P53 regulates the expression of histone modifiers to restrict stemness and maintain differentiated luminal identity in breast cancer. Proc Natl Acad Sci 2025;122. 101073\/pnas\/2522646122.","DOI":"10.1073\/pnas.2522646122"},{"key":"1822_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40170-020-00234-5","volume":"10","author":"H De Vitto","year":"2020","unstructured":"De Vitto H, Ryu J, Calderon-Aparicio A, Monts J, Dey R, Chakraborty A, et al. Estrogen-related receptor alpha directly binds to p53 and cooperatively controls colon cancer growth through the regulation of mitochondrial biogenesis and function. Cancer Metab. 2020;10:28. https:\/\/doi.org\/10.1186\/s40170-020-00234-5.","journal-title":"Cancer Metab"},{"key":"1822_CR27","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/nrc2730","volume":"9","author":"D Menendez","year":"2009","unstructured":"Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets,. Nat Cancer Rev. 2009;9:724\u201337.","journal-title":"Nat Cancer Rev"},{"key":"1822_CR28","doi-asserted-by":"publisher","unstructured":"Shao C, Indeglia A, Foster M, Casey K, Leung J, Modarai SR, et al. Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer. Genes Devel. https:\/\/doi.org\/10.1101\/gad.352953.125.","DOI":"10.1101\/gad.352953.125"},{"key":"1822_CR29","doi-asserted-by":"publisher","unstructured":"Kummar S, Fellous M, and Levine AJ. The Roles of Mutant p53 in Reprograming and Inflammation in Breast Cancers, Cell Death Diff. https:\/\/doi.org\/10.1038\/.s41418-025-01549-w.","DOI":"10.1038\/.s41418-025-01549-w"},{"key":"1822_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1021\/acsmedchemlett.4c00379","volume":"16","author":"BT Vu","year":"2024","unstructured":"Vu BT, Dominique R, Fahr BJ, Li HH, Fry DC, Xu L, et al. Discovery of Rezatapopt (PC14586) a first in class small molecule reactivator of p53 Y220C mutant in development. ACS Med Chem Lett. 2024;16:34\u201339.","journal-title":"ACS Med Chem Lett"},{"key":"1822_CR31","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1200\/JCO.2022.40.16_suppl.3003","volume":"40","author":"EE Dumbrava","year":"2022","unstructured":"Dumbrava EE, Johnson ML, Tolcher AW, Shapiro G, Thompson JA, El-Khoueiry AB, et al. First in human study of PC14586, a small molecule structural corrector of Y220C mutant p53,in patients with advanced solid tumors harboring a TP53Y220C mutation. J Clin Oncol. 2022;40:3003.","journal-title":"J Clin Oncol"},{"key":"1822_CR32","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1158\/2159-8290.CD-24-1421","volume":"15","author":"AM Puzio-Kuter","year":"2025","unstructured":"Puzio-Kuter AM, Xu L, McBrayer MK, Dominique R, Li HH, Fahr BJ, et al. Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator. Cancer Discov. 2025;15:1159\u201379. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-1421.","journal-title":"Cancer Discov"},{"key":"1822_CR33","first-page":"LB","volume":"22","author":"AM Schram","year":"2025","unstructured":"Schram AM, Fellous M, LeDuke K, Schmid A, Dumbrava EE. Updated phase 1 results from the PYNNACLE phase 1 and 2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation. Mol Cancer Ther. 2025;22:LB.","journal-title":"Mol Cancer Ther"},{"key":"1822_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0092-8674(00)80626-1","volume":"101","author":"M Ollmann","year":"2000","unstructured":"Ollmann M, Young LM, Di Como CJ, Karim F, Belvin M, Robertson S, et al. Drosophila p53 is a structural and functional homolog of the tumor suppressor p53. Cell. 2000;101:91\u2013101. https:\/\/doi.org\/10.1016\/S0092-8674(00)80626-1.","journal-title":"Cell"},{"key":"1822_CR35","doi-asserted-by":"publisher","first-page":"903","DOI":"10.18632\/aging.100099","volume":"1","author":"M Waskar","year":"2009","unstructured":"Waskar M, Landis GN, Shen J, Curtis C, Tozer K, Abdueva D, et al. Drosophila melanogaster p53 has developmental stage-specific and sex-specific effects on adult life span indicative of sexual antagonistic pleiotropy. Aging. 2009;1:903\u201336. https:\/\/doi.org\/10.18632\/aging.100099.","journal-title":"Aging"},{"key":"1822_CR36","doi-asserted-by":"publisher","first-page":"7301","DOI":"10.1073\/pnas.97.13.7301","volume":"97","author":"S Jin","year":"2000","unstructured":"Jin S, Martinek S, Joo WS, Wortman JR, Mirkovic N, Sali A, et al. Identification and characterization of a p53 homologue in Drosophila melanogaster. PNAS. 2000;97:7301\u20137306.","journal-title":"PNAS"},{"key":"1822_CR37","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1038\/cdd.2011.120","volume":"18","author":"V Marcel","year":"2011","unstructured":"Marcel V, Dichtel-Danjoy ML, Sagne C, Hafsi H, Ma D, Ortiz-Cuaran S, et al. Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ. 2011;18:1815\u201324. https:\/\/doi.org\/10.1038\/cdd.2011.120.","journal-title":"Cell Death Differ"},{"key":"1822_CR38","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.c.cell.2024.09.009","volume":"42","author":"R Kudo","year":"2024","unstructured":"Kudo R, Sofionov A, Jones C, Moiso E. Dry Jr., et al. Long-term breast cancer response to CDK4\/6 inhibition defined by TP53-Mediated geroconversion. Cancer Cell. 2024;42:1983. https:\/\/doi.org\/10.1016\/j.c.cell.2024.09.009.","journal-title":"Cancer Cell"},{"key":"1822_CR39","doi-asserted-by":"publisher","first-page":"8563","DOI":"10.1158\/0008-5472.CAN-09-0259","volume":"69","author":"Lefkimmiatis","year":"2009","unstructured":"Lefkimmiatis, Caratozzolo MF, Merlo P, D\u2019Erchia M, Navarro B, Levrero M, et al. P73 and p63 Sustain Cellular Growth by Transcriptional Activation of Cell Cycle Progression Genes. Cancer Res. 2009;69:8563\u201371.","journal-title":"Cancer Res"},{"key":"1822_CR40","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1073\/pnas.79.8.2554","volume":"79","author":"JJ Hopfield","year":"1982","unstructured":"Hopfield JJ. Neural networks and physical systems with emergent collective computational abilities. Proc Natl Acad Sci Apr. 1982;79:2554\u20138. https:\/\/doi.org\/10.1073\/pnas.79.8.2554.","journal-title":"Proc Natl Acad Sci Apr"},{"key":"1822_CR41","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.1606.01164","author":"D Krotov","year":"2016","unstructured":"Krotov D, Hopfield JJ. Dense associative memory for pattern recognition. Adv Neural Inf Process Syst. 2016. https:\/\/doi.org\/10.48550\/arXiv.1606.01164.","journal-title":"Adv Neural Inf Process Syst"},{"key":"1822_CR42","doi-asserted-by":"publisher","first-page":"dev202997","DOI":"10.1242\/dev.202997","volume":"151","author":"O Karin","year":"2024","unstructured":"Karin O. EnhancerNet: a predictive model of cell identity dynamics through enhancer selection. Development. 2024;151:dev202997. https:\/\/doi.org\/10.1242\/dev.202997.","journal-title":"Development"},{"key":"1822_CR43","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41586-024-08391-z","volume":"637","author":"X Fu","year":"2025","unstructured":"Fu X, Mo S, Buendia A, Laurent AP, Shao A, Alvarez-Torres M, et al. A Foundation Model of Transcription across human cell types. Nature. 2025;637:965\u2013973.","journal-title":"Nature"},{"key":"1822_CR44","doi-asserted-by":"crossref","unstructured":"Levandowski CB, Jones T, Gruca M, Ramamoorthy S, Dowell RD, & Taatjes DJ. The \u039440 isoform inhibits p53-dependent eRNA transcription and enables regulation by signal-specific transcription factors during p53 activation, PLOS Biol. 2021. aug;19:e3001364.","DOI":"10.1371\/journal.pbio.3001364"},{"key":"1822_CR45","doi-asserted-by":"publisher","unstructured":"Arsic N, Slatter T, Gadea G, Villain E, Fournet A, Kazantseva M, et al. \u0394p63\u03b2 isoform pro-invasive activity is regulated through an aggregation-dependent mechanism in cancer cells, Nat Comm 2021; https:\/\/doi.org\/10.1038\/541467-021-25550-2.","DOI":"10.1038\/541467-021-25550-2"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01822-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01822-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01822-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:11:42Z","timestamp":1785517902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01822-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":45,"alternative-id":["1822"],"URL":"https:\/\/doi.org\/10.1038\/s41418-026-01822-6","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A. J. Levine is a founder, board member and consultant of a biotech company that synthesized and tested Rezatapopt, a mutant p53 reactivator. None of the other authors have any conflicts of interest in the ideas presented by this manuscript. Note of added proof, Ning Yao, Dima Krotov, David Hoyos and Benjamin Greenbaum have a manuscript submitted for publication that provides the mathematical basis for the neural networks and transcription factor networks discussed in this manuscript.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}